During year 3, clinical studies within the TransBioLine project are progressing in the enrolment of patients to move forward in the identification of novel biomarkers that reliably indicate specific organ injury during drug development.

Status of clinical studies per centre and organ work package as of 16 March 2022

Drug induced KIDNEY injury (WP1)Pre-eclampsiaanti-VEGF  
University of Zurich (CH)enrollingenrolling
University of Munich (GE)enrollingenrolling
University of Malaga/ Servicio Andaluz de Salud (ES)enrolling-
University of Bern (GE)approved-

Drug induced LIVER injury (WP2)DILIALFNAFLDMethotraxate
University of Nottingham (UK)enrollingenrollingenrollingenrolling
University of Zurich (CH)enrolling---
University of Munich (GE)enrolling---
University of Malaga/ Servicio Andaluz de Salud (ES)enrolling---
Landspitali University Hospital (IS)enrolling---
Assistance Publique – Hopitaux de Paris (FR)approved---
University of Bern (GE)enrolling---

Drug induced PANCREAS injury (WP3)MAP-1   
University of Liverpool (UK)approved
University of Munich (GE)not yet submitted
University of Malaga/ Servicio Andaluz de Salud (ES)approved

Drug induced VASCULAR injury (WP4)VasculitidesAngioplasty
University of Zurich (CH)enrollingenrolling
University of Malaga/ Servicio Andaluz de Salud (ES)enrolling-

Drug induced CNS injury (WP5)TBIMSChemoBrainNHV
Charité – Berlin University Hospital (GE)-completed completed completed
Pfizercompleted --enrolling

Liquid biopsies (WP6)NHV   
Janssenenrolling

 

enrolling: trial is running, patient recruitment is underway
approved: ethical approval has been received, patients not yet being recruited
submitted: study awaiting ethical approval, documents submitted to local ethical committee
not yet submitted: documents will be submitted for ethical approval shortly
completed: patients no longer being recruited
-: not planned/not applicable